Page last updated: 2024-11-13

ah 111585

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

AH 111585: an RGD-based integrin peptide-polymer conjugate for imaging breast cancer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25091062
CHEMBL ID3989518
SCHEMBL ID11928878
MeSH IDM0523286

Synonyms (25)

Synonym
D09903
fluciclatide f 18 (usan/inn)
SCHEMBL11928878
fluciclatide f 18
hh9ugu71p8 ,
18f-ah-111585
fluciclatide (18f) [inn]
fluciclatide (18f)
879894-01-6
18f-fluciclatide
6-n-((28e)-29-(4-((sup 18f))fluorophenyl)-5,25-dioxo-3,9,12,15,18,21,27-heptaoxa-6,24,28- triazanonacos-28-enoyl)-2-n-(2-sulfanylacetyl)-l-lysyl-l-cysteinyl-l-arginylglycyl-l-alpha- aspartyl-l-cysteinyl-l-phenylalanyl-1-n-(17-amino-13,17-dioxo-3,6,9,15-te
(18f)ah111585
ah 111585
fluciclatide f 18 [usan:inn]
unii-hh9ugu71p8
fluciclatide (f-18)
(18f)ah-111585
fluciclatide (18f) [who-dd]
fluciclatide f 18 [usan]
fluciclatide ((1)f) [inn]
ah-111585 f-18
fluciclatide f-18
DTXSID30236734
[18f]ah111585
CHEMBL3989518

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"U87-MG tumor uptake of (18)F-fluciclatide was determined by small-animal PET after longitudinal administration of the antiangiogenic agent sunitinib (a 2-wk dosing regimen)."( Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Allen, L; Barnett, J; Battle, MR; Goggi, JL; Morrison, MS, 2011
)
0.37
"Dynamic small-animal PET of (18)F-fluciclatide uptake after administration of the clinically relevant antiangiogenic agent sunitinib revealed a reduction in the tumor uptake of (18)F-fluciclatide compared with that in vehicle-treated controls over the 2-wk dosing regimen."( Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Allen, L; Barnett, J; Battle, MR; Goggi, JL; Morrison, MS, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's9 (75.00)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (16.67%)5.53%
Reviews2 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]